CN112716814B - 一种双层摇摇精华及其制备方法 - Google Patents
一种双层摇摇精华及其制备方法 Download PDFInfo
- Publication number
- CN112716814B CN112716814B CN202011597771.5A CN202011597771A CN112716814B CN 112716814 B CN112716814 B CN 112716814B CN 202011597771 A CN202011597771 A CN 202011597771A CN 112716814 B CN112716814 B CN 112716814B
- Authority
- CN
- China
- Prior art keywords
- parts
- essence
- skin
- water
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000003921 oil Substances 0.000 claims abstract description 27
- 239000003906 humectant Substances 0.000 claims abstract description 10
- 239000002562 thickening agent Substances 0.000 claims abstract description 9
- 239000004519 grease Substances 0.000 claims abstract description 7
- 239000003755 preservative agent Substances 0.000 claims abstract description 7
- 230000002335 preservative effect Effects 0.000 claims abstract description 7
- 239000012071 phase Substances 0.000 claims description 41
- 235000019198 oils Nutrition 0.000 claims description 22
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 17
- 239000008346 aqueous phase Substances 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 11
- 108010087806 Carnosine Proteins 0.000 claims description 11
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 11
- 229940044199 carnosine Drugs 0.000 claims description 11
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 11
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 10
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 9
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 9
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 8
- 244000144725 Amygdalus communis Species 0.000 claims description 8
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 8
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- 239000008168 almond oil Substances 0.000 claims description 8
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 7
- 229940032094 squalane Drugs 0.000 claims description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 6
- SHOKSIZSCQFIRY-UHFFFAOYSA-N [3-(2-tert-butyl-2-hydroxy-4,4-dimethyl-3-phenylpentanoyl)oxy-2,2-bis[(2-tert-butyl-2-hydroxy-4,4-dimethyl-3-phenylpentanoyl)oxymethyl]propyl] 2-tert-butyl-2-hydroxy-4,4-dimethyl-3-phenylpentanoate Chemical compound C=1C=CC=CC=1C(C(C)(C)C)C(O)(C(C)(C)C)C(=O)OCC(COC(=O)C(O)(C(C=1C=CC=CC=1)C(C)(C)C)C(C)(C)C)(COC(=O)C(O)(C(C=1C=CC=CC=1)C(C)(C)C)C(C)(C)C)COC(=O)C(O)(C(C)(C)C)C(C(C)(C)C)C1=CC=CC=C1 SHOKSIZSCQFIRY-UHFFFAOYSA-N 0.000 claims description 6
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 6
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims description 6
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 claims description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 5
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 5
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 5
- -1 polydimethylsiloxane Polymers 0.000 claims description 5
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- 229940035936 ubiquinone Drugs 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 claims description 3
- 125000001655 ubiquinone group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 8
- 230000037303 wrinkles Effects 0.000 abstract description 8
- 239000003795 chemical substances by application Substances 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 4
- 230000003750 conditioning effect Effects 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000004902 Softening Agent Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 78
- 239000000686 essence Substances 0.000 description 41
- 230000001815 facial effect Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 230000003712 anti-aging effect Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 9
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 8
- 230000003020 moisturizing effect Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000000245 forearm Anatomy 0.000 description 6
- 210000000434 stratum corneum Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 206010040925 Skin striae Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000010191 image analysis Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 102000055501 telomere Human genes 0.000 description 4
- 108091035539 telomere Proteins 0.000 description 4
- 210000003411 telomere Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 230000037373 wrinkle formation Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- OWPUOLBODXJOKH-UHFFFAOYSA-N 2,3-dihydroxypropyl prop-2-enoate Chemical compound OCC(O)COC(=O)C=C OWPUOLBODXJOKH-UHFFFAOYSA-N 0.000 description 1
- JFSQSDAOQLNSQI-DTBJPNGVSA-N 2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-(hexadecanoylamino)-3-methylbutanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O JFSQSDAOQLNSQI-DTBJPNGVSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 206010028164 Multiple allergies Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002199 base oil Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940072117 fennel extract Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940077272 palmitoyl hexapeptide-12 Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/03—Liquid compositions with two or more distinct layers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
- A61K2800/72—Hypo-allergenic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
Abstract
本发明属于化妆品技术领域,公开了一种双层摇摇精华及其制备方法。其中,本发明提供的双层摇摇精华,包括水相和油相,所述水相以质量份计,包括:15‑20份保湿剂、0.1‑0.5份增稠剂、0.1‑1份防腐剂、0.05‑0.2份pH调节剂、75‑85份水;所述油相以质量份计,包括:50‑65份柔润剂、30‑50份油脂、0.2‑0.8份皮肤调理剂、0.05‑0.1份香精。本发明提供的双层摇摇精华在科学配比下能够发挥活性成分的超强搭配作用,减少初老症状产生的干燥、皮肤粗糙、暗沉、产生皱纹等问题。
Description
技术领域
本发明涉及化妆品技术领域,特别是涉及一种双层摇摇精华及其制备方法。
背景技术
随着现代生活节奏的加快和社会各种压力的增大,以及环境污染等各种影 响,不少在25-35岁的年轻人群的皮肤可能已经出现了细纹、脸色暗黄、皮肤粗 糙等初老症状。虽然目前市面上存在许多抗衰老的护肤产品,但大多抗衰老产 品并没有区分使用人群,由于不同年龄阶段的皮肤状况是不完全相同的,因此 如40岁以上人群的皮肤老化,与25-35岁年轻人群的皮肤产生的初老症状也并不 完全相同。
中国专利CN111568823A公开了一种紧致肌肤、抗初老的精华液及其制备方 法。该精华液由海藻糖、烟酰胺、乳化剂、防腐剂、泛醇、二丙二醇、甘油丙 烯酸酯/丙烯酸共聚物、甘油聚醚-26、pH调节剂、增稠剂、香精、海茴香提取物、 透明质酸钠、丁二醇、油橄榄果提取物、棕榈酰六肽-12、水解酵母提取物、聚 季铵盐-51、吡咯烷酮羧酸钠/甜菜碱/山梨糖醇/甘氨酸/丙氨酸/脯氨酸/丝氨酸/苏 氨酸/精氨酸和水组成,其抗氧化、美白、锁水保湿、紧致肌肤效果优异,即对于衰老受损肌肤具有很好的修复效果,然而该专利提供的精华液对皮肤初老症 状主要产生的皮肤粗糙、皱纹生成并没有显著功效。
如此,随着市场化的愈加细分以及年轻人群对护肤品功效追求的提高,本 领域研发人员针对不断扩大的市场需求有必要开发一种适合年轻人群的、全面 抗初老的护肤产品。
发明内容
为了克服上述现有技术的缺点与不足,本发明首要目的是提供一种功效良 好的全面抗初老双层摇摇精华。
本发明另一目的在于提供上述双层摇摇精华的制备方法。
为实现上述发明目的,本发明采用如下技术方案:
一种双层摇摇精华,包括水相和油相,所述水相以质量份计,包括:15-20 份保湿剂、0.1-0.5份增稠剂、0.1-1份防腐剂、0.05-0.2份pH调节剂、75-85份 水;所述油相以质量份计,包括:50-65份柔润剂、30-50份油脂、0.2-0.8份皮 肤调理剂、0.05-0.1份香精。
优选的,所述水相和所述油相的质量比为3:1-4:1,更优选为4:1。
优选的,以质量份计,所述水相还包括0.05-0.2份肌肽、1-3份烟酰胺。
优选的、所述的保湿剂可包括木糖醇、PCA钠、1,3-丁二醇、1,2-己二醇中 的至少一种。
优选的,所述木糖醇、所述PCA钠、所述1,3-丁二醇和所述1,2-己二醇 的质量比为10:5:0.5:0.5。
优选的,所述增稠剂包括纤维素胶、藻酸钠中的至少一种。
优选的,所述pH调节剂可包括柠檬酸、磷酸氢二钠中的至少一种。
优选的,所述水可以是去离子水、纯净水或蒸馏水中的至少一种。
优选的,所述水相通过所述pH调节剂调节pH为5.0-6.0。
优选的,所述防腐剂可包括乙基己基甘油、对羟基苯乙酮中的至少一种。
优选的,所述皮肤调理剂可包括季戊四醇四(双-叔丁基羟基氢化肉桂酸) 酯、生育酚乙酸酯、泛醌中的至少一种。
优选的,所述水相还可包括着色剂,使所述双层精华的外观更加美观。
优选的,所述着色剂可包括CI 19140、CI 16035中的至少一种。
优选的,所述柔润剂可包括异十六烷、聚二甲基硅氧烷中的至少一种。
优选的,所述油脂可包括甜扁桃油、角鲨烷中的至少一种。
优选的,所述甜扁桃油和所述角鲨烷的质量比为1:1。
优选的,所述双层摇摇精华,包括水相和油相,其中所述水相以质量份计, 包括0.05-0.2份肌肽、1-3份烟酰胺、9-12份木糖醇、4-6份PCA钠、0.1-1份 1,3-丁二醇、0.1-1份1,2-己二醇、0.1-0.5份纤维素胶和海藻酸钠混合物、0.1-0.5 份乙基己基甘油、0.1-0.5份对羟基苯乙酮、0.05-0.1份柠檬酸、0.05-0.1份磷酸 氢二钠、75-85份水;所述油相以质量份计,包括:35-40份异十六烷、15-25份 甜扁桃油、15-25份角鲨烷、15-25份聚二甲基硅氧烷、0.05-0.2份季戊四醇四(双 -叔丁基羟基氢化肉桂酸)酯、0.1-0.5份生育酚乙酸酯、0.01-0.05份泛醌、0.05-0.1 份香精。
本发明配方中:
本发明采用的肌肽对皮肤的抗衰老作用机制主要有四:①通过减少线粒体功 能损伤、抗氧化等清除自由基或者减少自由基的产生抗衰老作用;②端粒的长 度与细胞分裂次数成正比,在出生时端粒长度最长,随着年龄的增长便会逐渐 缩短,肌肽能够激活端粒酶,抑制端粒缩短,进而延缓衰老;③肌肽能够保护 弹性蛋白及胶原蛋白不被糖基化,从而减少糖基化蛋白质的交联导致的细胞间 营养及代谢产物的交换障碍,最终减少皮肤弹性下降及皱纹产生;④肌肽能够使衰老的细胞恢复活力。
本发明采用的烟酰胺是一种水溶性、稳定、易穿透角质层的小分子维生素, 能够有效抑制黑色素颗粒的形成和黑色素向角质层细胞传递,当有部分黑色素 不可避免的达到表层皮肤后,又能通过加速皮肤细胞的更新速度从而促进含有 黑色素的细胞脱落,从内到外净白肌肤,从而减少初老皮肤出现的肤色暗沉, 并对皮肤有提亮的作用。
本发明中采用天然植物保湿剂木糖醇、皮肤天然保湿因子PCA钠、1,3-丁二 醇、1,2-己二醇均为小分子保湿剂,具有分子量小,渗透性强,容易进入角质细 胞间隙,能够起到即时保湿作用。
本发明采用的角鲨烷是皮肤中的一种天然成分,有较好的抗氧化和刺激免 疫力的作用,能快速地与肌肤内的水分和油脂相溶。形成天然的皮肤保护屏障, 稳定性极佳,不会与空气、紫外线等发生氧化作用,能有效保护皮肤不受外界 物质的侵害,具有极佳的渗透力,高效的携氧性,能调整肌肤的水油平衡,避 免皮肤粗糙、暗沉、使肌肤恢复原本的柔嫩触感,是肌肤的润滑油,能够补充皮肤天然油脂。
本发明采用的甜扁桃油含有多种维生素、蛋白质、多元不饱和脂肪酸、矿 物质以及葡萄糖苷,是相当轻柔、润滑、不油腻的基础油,具有滋养与保湿, 舒缓和抗过敏的作用。
本发明皮肤调理剂中采用季戊四醇四(双-叔丁基羟基氢化肉桂酸)酯能消 除自由基,具有抗氧化作用,可防止衰老;生育酚乙酸酯具有很好的抗氧化效 果,是一种油溶性的天然物质,对肌肤有很好的营养滋润作用,可以促进伤口 愈合、预防发炎、防止肌肤粗糙皲裂,改善黑斑,还能避免油脂的酸败氧化; 泛醌是一种强亲脂性抗氧化剂,作为一种小分子物质能够很容易穿透肌肤,起 到提高皮肤修复再生能力,减少自由基损伤,可预防光老化和皱纹生成。
本发明还提供上述双层摇摇精华的制备方法,包括以下步骤:
(1)水相的制备:按比例将增稠剂加入水中,混合均匀,均质2-3min,得 到水相A;将防腐剂加入部分保湿剂中,加热搅拌溶解得到水相B;将水相B加 入水相A混合均匀,降温后加入剩余保湿剂混合均匀,并用pH调节剂调节pH为 5.0-6.0,得到所述水相;
(2)油相的制备:按比例将柔润剂、油脂、皮肤调理剂、香精,混合均匀 得到油相;
(3)双层精华的制备:将水相和油相按3:1-4:1的质量比加入容器。
优选的,步骤(1)中将增稠剂在水中混合均匀后在80-85℃条件下保温 10-15min。
优选的,步骤(1)中所述加热为加热至60-65℃,所述降温为降温至40-45℃。
优选的,当所述双层摇摇精华还包括肌肽、烟酰胺时,所述肌肽和所述烟 酰胺在降温后与所述剩余保湿剂一同加入混合均匀。
相比于现有技术,本发明具有如下优点和技术效果:
(1)本发明提供的双层摇摇精华采用全面抗初老配方组合及水油黄金配比, 精华水保湿联合精华油滋养起到协同抗初老的功效,尤其适合年轻人群皮脂腺 较发达的皮肤,具有相当好的亲肤性和良好的使用感,能够打造水油平衡的健 康肌底,同时在科学配比下发挥活性成分的超强搭配作用,减少初老症状产生的干燥、皮肤粗糙、暗沉、产生皱纹等问题。
(2)本发明提供的双层摇摇精华不使用表面活性剂,对皮肤更加温和无刺 激。
(3)本发明提供的双层摇摇精华由水相和油相两相组成,制备过程中不涉 及乳化操作,因此该精华的制备工艺简单,工艺时间短,效率高,适合规模化 生产。
附图说明
为了更清楚地说明本发明实施例的技术方案,下面将对实施例中所需要使 用的附图作简单地介绍,应当理解,以下附图仅示出了本发明的某些实施例, 因此不应被看作是对范围的限定,对于本领域普通技术人员来讲,在不付出创 造性劳动的前提下,还可以根据这些附图获得其他相关的附图。
图1为使用实施例1样品的前臂内侧皮肤含水量变化柱形图;
图2为实施例1一名受试者在不同的时间点面部产品区域明亮度的变化;
图3为实施例1一名受试者在不同的时间点面部产品区域细纹的变化;
图4为实施例1一名受试者在不同的时间点面部产品区域法令纹的变化;
图5为实施例1三名受试者在不同的时间点面部产品区域3D法令纹的变化;
图6为实施例1所有受试者在使用产品后的自我评价结果。
具体实施方式
下面结合具体实施例和附图对本发明作进一步详细的描述,但本发明的实 施方式不限于此。如无特别说明,本发明中所有原料和试剂均为市购常规的原 料、试剂。实施例中各组分的用量以质量体积份计,g、mL。
实施例1-5
实施例1-5的双层摇摇精华,以质量份计,包括如表1所示组分。
表1.实施例1-4组分表
将表1中的实施例1-5配方按照以下步骤进行制备:
(1)水相的制备:将纤维素胶、藻酸钠加入水中,混合均匀,加热至80-85℃ 后保温10-15min,均质2-3min,得到水相A;将对羟基苯乙酮、乙基己基甘油加 入1,3-丁二醇和1,2-己二醇的混合液中,加热至60-65℃搅拌溶解得到水相B;将 水相B加入水相A混合均匀,降温至40-45℃后加入木糖醇、肌肽、烟酰胺、PCA 钠、CI 19140、CI 16035混合均匀,并用柠檬酸和磷酸氢二钠调节pH为5.0-6.0, 得到所述水相;
(2)油相的制备:按比例将聚二甲基硅氧烷、异十六烷、角鲨烷、甜扁桃 油、季戊四醇四(双-叔丁基羟基氢化肉桂酸)酯、生育酚乙酸酯、泛醌、香精 混合均匀得到油相;
(3)双层精华的制备:将水相和油相按不同质量比加入容器。
空白对照组
空白对照组不涂抹任何产品。
对比例1
对比例1与实施例5的区别为对比例1的样品中水相和油相的质量比为5:1,其 他试剂用量和制备方法与实施例5相同。
对比例2
对比例2与实施例5的区别为不含皮肤调理剂,其他试剂用量和制备方法与 实施例5相同。
抗初老功效测试
以实施例1、实施例5和对比例1-2所制备的双层摇摇精华为例进行抗初老功 效测试。
测试方法:左右脸和手臂随机对照,双盲测试
受试者要求:本次测试受试者筛选自彭氏(惠州)实业发展有限公司工厂, 选择符合如下入选和排除标准的健康受试者:
入选标准:
(1)年龄25~35岁健康女性;
(2)肤色暗沉,失去光泽,皮肤略松弛;
(3)皮肤较粗糙,不够紧致,已出现细纹;
(4)能很好配合试验者,在研究期间能保持生活的规律性;
(5)能够阅读和理解知情,同意书所有内容,并自愿签署知情同意书;
(6)试验期间不再参与其他任何研究中心的临床试验;
(7)试验期间同意不使用任何对结果有影响的化妆品、药物和保健品。
排除标准:
(1)测试部位有皮肤疾病或者瑕疵而可能影响试验结果判断者;
(2)高度过敏体质者;
(3)妊娠、哺乳或在测试期间打算怀孕的女性;
(4)有严重心、肝、肾功能损害及严重免疫功能低下者,或近一个月内使用 免疫抑制剂者;
(5)有精神疾病、严重内分泌疾病以及口服避孕药者;
(6)30d内参加药物临床试验者或其它试验者,或近1周内系统使用对试验结 果有影响的药物者;
(7)2周内有口服和外用可能对试验结果有影响的美容产品者;
(8)不能配合试验者。
数据统计:数据使用SPSS进行统计,对测试数据进行正态分布检验,若测 试数据为正态分布,则采用t检验方法进行统计分析;若测试数据为非正态分布, 则采用秩和检验方法进行统计分析,统计方法均采用双尾检验,检验水准α=0.05。
测试项目:
(1)短期保湿——皮肤含水量测试
将实施例1、实施例5的样品精华按(2.0±0.1)mg/cm2的用量在前臂内侧进 行单次涂布,均匀涂抹测试区域内,然后采用皮肤水分测试仪(德国CKCorneometer CM825)在使用前、15min、45min、1h、2h测试左右前臂内侧 测试区域的皮肤含水量,具体结果如表1,图1为使用实施例1样品的前臂内侧皮 肤含水量变化柱形图。
表1受试者在不同的时间点前臂内侧角质层水分含量(x±s)
皮肤水分测定仪CorneometerCM 825用于检测皮肤角质层水分含量,皮肤 角质层水分含量测量值越高,说明皮肤角质层水分含量越高。由表1数据可见, 实施例1在15min、45min、1h、2h,实施例1组前臂内侧皮肤角质层水分含量变化值与使用前皮肤水分含量变化值的数据差异,均具有统计学意义(P<0.05) 同时,两组(实施例1组和空白对照组)的测定值与初始值的差值在15min、45min、 1h、2h都具有显著性差异(P<0.05)。实验数据表明,本发明提供的双层摇摇 精华具有短期提高皮肤含水量的作用,尤其当糖醇、PCA钠、1,3-丁二醇、1,2- 己二醇以特定比例和用量联用时,其提皮肤含水量能够极显著提高。
(2)经皮水分流失—皮肤屏障
将实施例1、实施例5设为一组和对比例1和对比例2设为为一组,在洁面后, 将样品精华摇匀,然后取3滴于掌心,分别涂抹于受试者左右脸颊,揉搓双手直 至温热,轻轻包裹住脸,帮助吸收,早晚两次,持续4周,同时采用经皮水分流 失测试探头(德国CKTewameter TM Hex)检测左右脸颊颧骨皮肤在使用前,使 用2周,使用4周的经皮水分流失率(TEWL),具体结果如表2。
表2受试者在不同的时间点面部测试区域TEWL值的变化
经皮水分流失测试探头(德国CKTewameter TM Hex)检测皮肤经皮水分流 失率,皮肤经皮水分流失率越低,表明皮肤屏障功能越好。由表2的数据可看出, 与对比例1-2相比,实施例1和实施例2能够更好的降低经皮水分流水,即说明在 在特定油水比例和组分下,在28天的使用周期内,双层摇摇精华能够降低皮肤 经皮水分流失率,提高皮肤屏障功能。
(3)面部成像测试
将实施例1、实施例5设为一组和对比例1和对比例2设为为一组,在洁面后, 将样品精华摇匀,揉搓双手直至温热,轻轻包裹住脸,帮助吸收,早晚两次, 持续4周,同时采用美国CANFIELD第七代面部成像分析仪VISIA拍摄受试者使 用前,使用后2周、使用后4周的面部图像,并对明亮度(ITA值)、面部细纹、 面部粗糙度、面部法令纹进行分析。
①明亮度(ITA°值)
利用VISIA图像分析系统结合Image-Pro皮肤综合分析软件,选取受试者左右 脸颊进行ITA°值计算,ITA是与L和b相关的表征皮肤明亮的数值,ITA°值越大, 皮肤越明亮,反之,皮肤越暗沉,其中实施例1与对比例1的测试结果如表3,图 2为实施例1一名受试者在不同的时间点面部产品区域明亮度的变化。
表3受试者在不同的时间点面部ITA°值
由表3数据可看出,与对比例1和对比例2相比,实施例1和实施例5的双层摇 摇精华均能够提高受试者面部ITA°值,即具有改善初老症状的皮肤暗沉情况。 其中,实施例1作为本发明的较佳实施例,其在D28的ITA°值与使用前比较,数 据具有统计学意义(P<0.05),同时从图2可看出,在使用28天后,实施例1受试 者脸部皮肤暗沉状况改善,有显著提亮效果,可见在特定配方比例下的双层摇 摇精华改善皮肤暗沉的功效显著提升。
面部细纹
利用VISIA图像分析系统结合Image-Pro皮肤综合分析软件,选取受试者左右 脸颊进行面部细纹计算,具体结果如表4,图3为实施例1一名受试者在不同的时 间点面部产品区域细纹的变化。
表4受试者在不同的时间点面部细纹变化
由表4数据可看出,与对比例1和对比例2相比,实施例1和实施例5的样品精 华具有减少面部细纹的作用,其中,实施例1作为本发明的较佳实施例,在D28 的面部细纹值与使用前比较,数据具有统计学意义(P<0.05),同时从图2可看 出,在使用28天后,实施例1受试者脸部细纹明显减少,皮肤更加平整,可见实 施例1的双层摇摇精华能够明显改善初老症状的细纹增多的症状。
③面部粗糙度
利用VISIA图像分析系统结合Image-Pro皮肤综合分析软件,选取受试者左右 脸颊进行面部纹理的计算,具体结果如表5。
表5受试者在不同的时间点面部纹理变化
由表5数据可看出,实施例1组和实施例5在D28的面部细纹值与使用前比较, 数据均具有统计学意义(P<0.05),而对比例1和对比例2在D14、D28的面部细纹 值与使用前比较,数据均不具有统计学意义(P>0.05),可见实施例1的双层摇摇 精华在特定配方条件下能够明显改善初老症状的皮肤粗糙情况。
④面部法令纹
利用VISIA图像分析系统结合Image-Pro皮肤综合分析软件,选取受试者左右 法令纹位置进行线性光强度的计算。利用线性光强度工具特定区域划线,像素 点的数据浮动越大,低谷的位置越低,皱纹越深,具体测试结果如表6,图4为 实施例1一名受试者在不同的时间点面部产品区域法令纹的变化;图5为实施例1 三名受试者在不同的时间点面部产品区域3D法令纹的变化。
表6受试者在不同的时间点面部法令纹变化
由表6数据可看出,与对比例1和对比例2相比,实施例1和实施例5均具有显 著的对抗法令纹的效果,其中实施例1和实施例5组在持续使用样品精华后脸部 的法令纹与使用前相比均有极显著改善(P<0.05),而对比例1和对比例2组在使 用后与使用前无显著性差异。同时,由图4、图5受试者面部法令纹的变化图可 见,在使用实施例1的双层摇摇精华后,多名受试者的法令纹有明显变浅。
功效总结:由实施例1、实施例5与对比例1和对比例2的功效比较中可以 看出,对比例1-2在缺少某些特定组分或比例用量不同的条件下,虽然具有一定 的改善皮肤的作用,但是效果并不显著,说明本发明提供的双层摇摇精华其显著的抗初老功效是通过配方中不同组分协同作用产生,在特定的组分选择、特 定的比例和用量范围条件下,本发明提供的双层摇摇精华具有良好的瞬时保湿、 保护皮肤屏障、减少脸部暗沉、减少脸部粗糙、对抗细纹和法令纹等全面抗初 老功效。
(4)受试者自我评价
对所有受试者进行问卷调查,问卷调查是受试者对使用实施例1产品的主观 评价,主要评价项目有:面部细纹、皮肤弹性、肤色亮度、肌肤的细腻程度、 肌肤的平滑度等,具体结果如图6。
由图6可见,志愿者对于使用28天双层摇摇精华后自我评价结果为:面部细 纹减少70.8%,肌肤增加弹性70.8%,肤色提亮70.8%,肌肤的细腻程度改善了 70.8%,肌肤平滑的改善了73.9%。同时,受试者对使用双层摇摇精华能改善皮 肤的满意度为100%。
实施例2-4所制备得到样品的功效评价结果与实施例1结果相近。
皮肤不良方应
使用样品期间,0例受试者出现局部红斑、丘疹、风团、水肿或全身的皮肤 不良方应。
上述实施例为本发明探索的最优实施方式,但本发明的实施方式并不受上 述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、 修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范 围之内。
Claims (1)
1.一种双层摇摇精华的制备方法,其特征在于,
所述双层摇摇精华由水相和油相组成,所述水相和所述油相的质量比为3:1-4:1;
以质量份计,所述水相包括0.05-0.2份肌肽、1-3份烟酰胺、9-12份木糖醇、4-6份PCA钠、0.1-1份1,3-丁二醇、0.1-1份1,2-己二醇、0.1-0.5份纤维素胶和藻酸钠混合物、0.1-0.5份乙基己基甘油、0.1-0.5份对羟基苯乙酮、0.05-0.1份柠檬酸、0.05-0.1份磷酸氢二钠和75-85份水;
以质量份计,所述油相包括35-40份异十六烷、15-25份甜扁桃油、15-25份角鲨烷、15-25份聚二甲基硅氧烷、0.05-0.2份季戊四醇四(双-叔丁基羟基氢化肉桂酸)酯、0.1-0.5份生育酚乙酸酯、0.01-0.05份泛醌和0.05-0.1份香精;
所述水相还包括着色剂,所述着色剂包括CI 19140、CI 16035中的至少一种;
所述木糖醇、所述PCA钠、所述1,3-丁二醇和所述1,2-己二醇的质量比为10:5:0.5:0.5;
所述甜扁桃油和所述角鲨烷的质量比为1:1;
所述木糖醇、PCA钠、1,3-丁二醇、1,2-己二醇组成保湿剂;
所述纤维素胶和藻酸钠混合物为增稠剂;
所述柠檬酸、磷酸氢二钠组成pH调节剂;
所述乙基己基甘油、对羟基苯乙酮组成防腐剂;
所述异十六烷、聚二甲基硅氧烷组成柔润剂;
所述甜扁桃油、角鲨烷组成油脂;
所述季戊四醇四(双-叔丁基羟基氢化肉桂酸)酯、生育酚乙酸酯、泛醌组成皮肤调理剂;
所述制备方法包括以下步骤:
(1)水相的制备:按比例将增稠剂加入水中,混合均匀,均质2-3min,得到水相A;将防腐剂加入部分保湿剂中,加热搅拌溶解得到水相B;将水相B加入水相A混合均匀,降温后加入剩余保湿剂混合均匀,并用pH调节剂调节pH为5.0-6.0,得到所述水相,其中所述肌肽和所述烟酰胺在降温后与所述剩余保湿剂一同加入混合均匀;
(2)油相的制备:按比例将柔润剂、油脂、皮肤调理剂、香精,混合均匀得到油相;
(3)双层精华的制备:将水相和油相按3:1-4:1的质量比加入容器;
步骤(1)中所述增稠剂在水中混合均匀后在80-85℃条件下保温10-15min;所述加热为加热至60-65℃,所述降温为降温至40-45℃。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011597771.5A CN112716814B (zh) | 2020-12-29 | 2020-12-29 | 一种双层摇摇精华及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011597771.5A CN112716814B (zh) | 2020-12-29 | 2020-12-29 | 一种双层摇摇精华及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112716814A CN112716814A (zh) | 2021-04-30 |
| CN112716814B true CN112716814B (zh) | 2023-07-11 |
Family
ID=75611372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011597771.5A Active CN112716814B (zh) | 2020-12-29 | 2020-12-29 | 一种双层摇摇精华及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112716814B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113616541B (zh) * | 2021-08-27 | 2022-04-12 | 广东丸美生物技术股份有限公司 | 一种双层精华及其制备方法 |
| CN113693973A (zh) * | 2021-10-09 | 2021-11-26 | 广州珈纳生物科技有限公司 | 一种双层精华水及其制备方法 |
| CN114288194B (zh) * | 2021-12-30 | 2024-03-22 | 彭氏(惠州)实业发展有限公司 | 一种不含去离子水的双层护肤精华液及其制备方法 |
| CN115024987A (zh) * | 2022-05-31 | 2022-09-09 | 彭氏(惠州)实业发展有限公司 | 具有修护和保湿功效的三层精华液及其制备方法与应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107496212A (zh) * | 2017-09-22 | 2017-12-22 | 广东檀馨护肤品有限公司 | 一种含有檀香油和精华成分的润肤霜剂及制备方法 |
| CN108653142A (zh) * | 2018-07-01 | 2018-10-16 | 佛山文森特知识产权服务有限公司 | 一种保湿组合物 |
| CN110169946A (zh) * | 2019-05-30 | 2019-08-27 | 科索瑞生物科技(天津)有限公司 | 眼部精华乳及其制备方法 |
| CN111000783A (zh) * | 2020-01-06 | 2020-04-14 | 彭氏(惠州)实业发展有限公司 | 一种美白舒缓抗衰精华及其制备方法 |
-
2020
- 2020-12-29 CN CN202011597771.5A patent/CN112716814B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107496212A (zh) * | 2017-09-22 | 2017-12-22 | 广东檀馨护肤品有限公司 | 一种含有檀香油和精华成分的润肤霜剂及制备方法 |
| CN108653142A (zh) * | 2018-07-01 | 2018-10-16 | 佛山文森特知识产权服务有限公司 | 一种保湿组合物 |
| CN110169946A (zh) * | 2019-05-30 | 2019-08-27 | 科索瑞生物科技(天津)有限公司 | 眼部精华乳及其制备方法 |
| CN111000783A (zh) * | 2020-01-06 | 2020-04-14 | 彭氏(惠州)实业发展有限公司 | 一种美白舒缓抗衰精华及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 化妆品抗衰老的原理与应用;李全 等;《中国美容医学》;20171115;第26卷(第11期);135-138 * |
| 幻容焕彩光感美颜精华液;广州品赫生物科技有限公司;《国产非特殊用途化妆品备案服务平台http://ftba.nmpa.gov.cn:8181/ftban/itownet/hzp_ba/fw/pz.jsp?processid=20200815104824tvd93&nid=20200815104824tvd93》;20200826;1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112716814A (zh) | 2021-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112716814B (zh) | 一种双层摇摇精华及其制备方法 | |
| US11911498B2 (en) | Low pH skin care composition and methods of using the same | |
| US6468564B1 (en) | Topical compositions containing lotus for skin treatment | |
| US11583488B2 (en) | Method of improving penetration of a vitamin B3 compound into skin | |
| CN112618456B (zh) | 一种控油收敛套装及其使用方法 | |
| CN110302091B (zh) | 一种含烟酰胺腺嘌呤二核苷酸的抗皮肤衰老组合物及其制备方法和用途 | |
| TW200538155A (en) | Methods and compositions for the treatment of skin changes associated with aging and environmental damage | |
| Schmitt | Skin-care products | |
| JP2000247866A (ja) | 皮膚外用剤 | |
| US20200038308A1 (en) | Wrinkle reducing compositions and methods | |
| CN110179687B (zh) | 一种多效修护多肽组合物及其在化妆品中的应用 | |
| EP1543821A1 (en) | External preparation | |
| CN115154375A (zh) | 一种稳定且具有修护及舒缓功效的清洁组合物 | |
| CN116473864A (zh) | 一种小分子肽多维透皮方法及其应用 | |
| US20130131160A1 (en) | New use of hesperetin | |
| CN113925802A (zh) | 一种舒缓抗刺激护肤面霜及其制备方法 | |
| CN112656717A (zh) | 一种双层面膜及其制备方法 | |
| JPS59216812A (ja) | 頭髪育毛料 | |
| CN108703917B (zh) | 一种抗衰老组合物及其制备的化妆品 | |
| CN117414313A (zh) | 一种保湿组合物及其应用 | |
| CN116158989A (zh) | 一种修护舒安组合物及其应用 | |
| US11260011B2 (en) | Use of neohesperidin | |
| CN114948769A (zh) | 一种具有舒缓修复效果的乳化型涂抹面膜 | |
| CN111603405A (zh) | 一种美白抗衰组合物以及含有该组合物的护肤品 | |
| CN112402309A (zh) | 一种多维矿物精华霜及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |